BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 26416448)

  • 1. MicroRNAs as prognostic molecular signatures in renal cell carcinoma: a systematic review and meta-analysis.
    Gu L; Li H; Chen L; Ma X; Gao Y; Li X; Zhang Y; Fan Y; Zhang X
    Oncotarget; 2015 Oct; 6(32):32545-60. PubMed ID: 26416448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The miR(21/10b) ratio as a prognostic marker in clear cell renal cell carcinoma.
    Fritz HKM; Lindgren D; Ljungberg B; Axelson H; Dahlbäck B
    Eur J Cancer; 2014 Jul; 50(10):1758-1765. PubMed ID: 24793999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer stem cell markers predict a poor prognosis in renal cell carcinoma: a meta-analysis.
    Cheng B; Yang G; Jiang R; Cheng Y; Yang H; Pei L; Qiu X
    Oncotarget; 2016 Oct; 7(40):65862-65875. PubMed ID: 27588469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA expression profiling of Xp11 renal cell carcinoma.
    Marchionni L; Hayashi M; Guida E; Ooki A; Munari E; Jabboure FJ; Dinalankara W; Raza A; Netto GJ; Hoque MO; Argani P
    Hum Pathol; 2017 Sep; 67():18-29. PubMed ID: 28411178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Characterization of Renal Cell Carcinoma: A Potential Three-MicroRNA Prognostic Signature.
    Lokeshwar SD; Talukder A; Yates TJ; Hennig MJP; Garcia-Roig M; Lahorewala SS; Mullani NN; Klaassen Z; Kava BR; Manoharan M; Soloway MS; Lokeshwar VB
    Cancer Epidemiol Biomarkers Prev; 2018 Apr; 27(4):464-472. PubMed ID: 29440068
    [No Abstract]   [Full Text] [Related]  

  • 6. MicroRNA-15a tissue expression is a prognostic marker for survival in patients with clear cell renal cell carcinoma.
    Mytsyk Y; Borys Y; Tumanovska L; Stroy D; Kucher A; Gazdikova K; Rodrigo L; Kruzliak P; Prosecky R; Urdzik P; Dosenko V
    Clin Exp Med; 2019 Nov; 19(4):515-524. PubMed ID: 31440867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of Expression of MicroRNAs in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Zhan B; Lu D; Luo P; Wang B
    Clin Lab; 2016 Nov; 62(11):2203-2211. PubMed ID: 28164670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of meta-signature miRNAs in renal cell carcinoma: an integrated miRNA expression profiling analysis.
    Tang K; Xu H
    Sci Rep; 2015 May; 5():10272. PubMed ID: 25974855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CircRNA cRAPGEF5 inhibits the growth and metastasis of renal cell carcinoma via the miR-27a-3p/TXNIP pathway.
    Chen Q; Liu T; Bao Y; Zhao T; Wang J; Wang H; Wang A; Gan X; Wu Z; Wang L
    Cancer Lett; 2020 Jan; 469():68-77. PubMed ID: 31629934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An increased level of MiR-222-3p is associated with TMP2 suppression, ERK activation and is associated with metastasis and a poor prognosis in renal clear cell carcinoma.
    Lyu J; Zhu Y; Zhang Q
    Cancer Biomark; 2020; 28(2):141-149. PubMed ID: 32116235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-23a-3p acts as an oncogene and potential prognostic biomarker by targeting PNRC2 in RCC.
    Quan J; Pan X; Li Y; Hu Y; Tao L; Li Z; Zhao L; Wang J; Li H; Lai Y; Zhou L; Lin C; Gui Y; Ye J; Zhang F; Lai Y
    Biomed Pharmacother; 2019 Feb; 110():656-666. PubMed ID: 30551118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated Phenotypic/Genotypic Analysis of Papillary Renal Cell Carcinoma Subtypes: Identification of Prognostic Markers, Cancer-related Pathways, and Implications for Therapy.
    Saleeb RM; Plant P; Tawedrous E; Krizova A; Brimo F; Evans AJ; Wala SJ; Bartlett J; Ding Q; Boles D; Rotando F; Farag M; Yousef GM
    Eur Urol Focus; 2018 Sep; 4(5):740-748. PubMed ID: 28753789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicalpathological and prognostic significance of survivin expression in renal cell carcinoma: a meta-analysis.
    Pu Z; Wang Q; Xie H; Wang G; Hao H
    Oncotarget; 2017 Mar; 8(12):19825-19833. PubMed ID: 28178644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNAs as prognostic molecular signatures in human head and neck squamous cell carcinoma: a systematic review and meta-analysis.
    Jamali Z; Asl Aminabadi N; Attaran R; Pournagiazar F; Ghertasi Oskouei S; Ahmadpour F
    Oral Oncol; 2015 Apr; 51(4):321-31. PubMed ID: 25677760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-566 functions as an oncogene and a potential biomarker for prognosis in renal cell carcinoma.
    Pan X; Quan J; Li Z; Zhao L; Zhou L; Jinling X; Weijie X; Guan X; Li H; Yang S; Gui Y; Lai Y
    Biomed Pharmacother; 2018 Jun; 102():718-727. PubMed ID: 29604591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic value of C-reactive protein in renal cell carcinoma: a systematic review and meta-analysis.
    Hu Q; Gou Y; Sun C; Ding W; Xu K; Gu B; Xia G; Ding Q
    Urol Oncol; 2014 Jan; 32(1):50.e1-8. PubMed ID: 24239465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215.
    White NM; Khella HW; Grigull J; Adzovic S; Youssef YM; Honey RJ; Stewart R; Pace KT; Bjarnason GA; Jewett MA; Evans AJ; Gabril M; Yousef GM
    Br J Cancer; 2011 Nov; 105(11):1741-9. PubMed ID: 22033272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of miR-183-5p predicts worse survival in patients with renal cell cancer after surgery.
    Li H; Pan X; Gui Y; Quan J; Li Z; Zhao L; Guan X; Xu J; Xu W; Lai Y
    Cancer Biomark; 2019; 24(2):153-158. PubMed ID: 30689558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNAs with prognostic significance in bladder cancer: a systematic review and meta-analysis.
    Xie Y; Ma X; Chen L; Li H; Gu L; Gao Y; Zhang Y; Li X; Fan Y; Chen J; Zhang X
    Sci Rep; 2017 Jul; 7(1):5619. PubMed ID: 28717125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. microRNA-210-3p depletion by CRISPR/Cas9 promoted tumorigenesis through revival of TWIST1 in renal cell carcinoma.
    Yoshino H; Yonemori M; Miyamoto K; Tatarano S; Kofuji S; Nohata N; Nakagawa M; Enokida H
    Oncotarget; 2017 Mar; 8(13):20881-20894. PubMed ID: 28152509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.